Session 48 - Vaccines & Vaccine Development

Friday, June 15 (12:45 PM - 2:15 PM), Poster & Exhibition Area

 
 

Abstract Title
48.001 Construction and evaluation of vaccine candidate fimH/fliC against Escherichia coli urinary tract infection
48.002 Antibody persistence and safety 3 years after CYD tetravalent dengue vaccination: follow-up results from a phase I trial in the Philippines
48.003 A mathematical model for the control of dengue using vaccines
48.004 Vaccination against viral hepatitis A and B in adults aged over 40 Years – antibody persistence and immune memory
48.005 Clinical impact and economic evaluation of organized HPV vaccination program in Hong Kong
48.006 The effect of oral immunization of kwashiorkor rat model with 38-kDa Mycobacterium tuberculosis protein to induce the secretion of intestinal and bronchial secretory immunoglobulin A (sIgA)
48.007 A prospective study comparing occurrence of post-vaccination fever among Thai children given either DTwP or DTaP- based vaccines
48.008 HPV vaccine coverage and social networks as tools for improvement
48.009 Awareness and acceptance of 2011- 2012 influenza vaccine among Indian HCP
48.010 Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa-HBV-IPV/Hib in Vietnamese infants
48.011 Assessment of the immunogenicity and safety of Quinvaxem® (DTwP-HepB- Hib) against diphtheria, pertussis, tetanus, hepatitis B and diseases caused by H. influenzae among healthy Vietnamese children
48.012 The Global Meningococcal Initiative (GMI): efforts to prevent and control meningococcal disease in India
48.013 Factors affecting participation in a typhoid vaccine trail in Pakistan
48.014 Immunogenicity of single-dose hepatitis A vaccines in young adults
48.015 Efficacy of mumps vaccine in Korea
48.016 A study of RotaTeq™ (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants
48.017 A five-year surveillance study (2007-2011) of invasive pneumococcal disease cases among childern of Ontario in Canada
48.018 Baculovirus system as a protein expression of influenza A/H1N1p virus
48.019 Adverse events following immunization from pandemic influenza A (H1N1) - Laos 2010
48.020 Invasive pneumococcal disease: impact of pneumococcal vaccination in South Australian children
48.021 Development of conjugate vaccines for enteric fever
48.022 Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies
48.023 Economic evidence for policy makers in Vietnam: dengue fever economic burden of disease and household willingness to pay for dengue vaccines
48.024 The Coalition against Typhoid (CaT): addressing barriers to typhoid vaccine implementation
48.025 Production of tissue culture rabies vaccine for human use in Nepal
48.026 Mode of Action (MoA) studies contribute to the safety evaluation of AS04 adjuvanted vaccines
48.027 Tuberculin skin test and BCG scar in children vaccinated at birth: a study from Iran    
48.028 The effect of propolis ethanol extract on humoral and cellular responses of mice immunized with Leishmania recombinant GP63 protein
48.029 Nasopharyngeal colonization of Streptococcus pneumoniae in elderly people, in Jakarta, Indonesia
48.030 Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America
48.031 Predicting conserved epitopes in the variants of amastin protein of Leishmania major and designig an epitope based immunogenic DNA vaccine
48.032 Update: serotype distribution and drug susceptibility of invasive pneumococcal diseases in central Thailand
48.033 Effect of rotavirus vaccination on rotavirus gastroenteritis in Thailand
48.034 The role of an independent entity in equitable access of vaccines in developing countries: A case from Pakistan
48.035 Effectiveness of herpes zoster vaccine on recurrent herpes zoster among an immunocompetent elderly population
48.036 Cross subclade immunity after one-year booster immunization with MF59®-adjuvanted A/H5N1 influenza vaccine in 6 month to 17 year-old children
48.037 Worldwide diversity and distribution of the malaria vaccine candidate MSP1-42: Implications for vaccine design
48.038 Hospital based surveillance of rotavirus gastroenteritis in children <5 years of age in Lebanon
   
   


International Society for Infectious Diseases
9 Babcock Street, Unit 3, Brookline MA 02446-5903 · USA
Phone: (617) 277-0551      ·      Fax: (617) 278-9113 · info@isid.org

© 2001-2010 International Society for Infectious Diseases. All Rights Reserved.
 


CD-ROM Produced by X-CD Technologies